
Corporate ActionJul 2, 2026, 02:01 AM
Abivax Raises $920M Gross Proceeds from Full Underwriters' Option Exercise
AI Summary
Abivax S.A. announced that the underwriters of its recent offering fully exercised their option to purchase an additional 960,000 American Depositary Shares (ADSs). This exercise brings the total number of ADSs issued in the offering to 7,360,000, resulting in gross proceeds of approximately $920.0 million (€807.4 million) for the company. The estimated net proceeds are $874.1 million (€767.1 million), which Abivax intends to use for the potential commercialization of its lead drug candidate, obefazimod, in the U.S., as well as for clinical research and development related to ulcerative colitis and Crohn's disease.
Key Highlights
- Underwriters fully exercised option to purchase 960,000 additional ADSs.
- Total ADSs issued in the offering now amount to 7,360,000.
- Gross proceeds from the offering reached approximately $920.0 million (€807.4 million).
- Estimated net proceeds, after expenses, are approximately $874.1 million (€767.1 million).
- Proceeds will fund potential commercialization of obefazimod in the United States.
- Funds also allocated for clinical R&D, primarily for ulcerative colitis and Crohn's disease.
- The offering price for the Additional ADSs was $125.00 per ADS.
Price Impact
More from ABVX